AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01876381
Drug: OPC-41061
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
Trial: NCT00185094
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00185094
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00185094
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00713687
Drug: Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1. Photodynamic therapy (PDT) after successful drainage:~   Photosan® 2 mg/kg i.v. 48 hrs before laser activation~2. 9 cycles of GemOx chemotherapy (start 4 weeks after PDT):~   * Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy~  * Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy~  * iteration every 14 days~  * afterwards 4 weeks intermission~3. Iteration of 1. and 2. in case of good compatibility
Trial: NCT00784121
Drug: Lactic Acid
RxNorm normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactic Acid (Dermacyd Breeze)
Trial: NCT02272127
Drug: icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04031729
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.
Trial: NCT00805584
Drug: desloratadine
RxNorm normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
Trial: NCT00332696
Drug: Octreotide LAR
RxNorm normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Octreotide long-acting release (LAR) 30 mg intramuscular injection.
Trial: NCT00332696
Drug: Octreotide (Immediate release)
RxNorm normalized name: octreotide Delayed Release Oral Capsule
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Immediate-release Octreotide supplied in 100 µg/mL ampules.
Trial: NCT00332696
Drug: methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
Trial: NCT00382174
Drug: Thymosin Beta 4
RxNorm normalized name: Thymosin beta 4
DrugBank: Thymosin beta-4 (DB12003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
Trial: NCT00961038
Drug: Ciprofloxacin (PulmoSphere, BAYQ3939)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
Trial: NCT00961038
Drug: Ciprofloxacin (PulmoSphere, BAYQ3939)
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
Trial: NCT01470157
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg/kg as oral suspension
Trial: NCT00461708
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg, PO, once per day
Trial: NCT00461708
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
Trial: NCT03621280
Drug: Levoketoconazole
RxNorm normalized name: LEVOKETOCONAZOLE
DrugBank: Levoketoconazole (DB05667)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levoketoconazole up to 1200 mg daily
Trial: NCT02638909
Drug: ceritinib
RxNorm normalized name: Ceritinib
DrugBank: Ceritinib (DB09063)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
Trial: NCT01306292
Drug: SonoVue
DrugBank: Sulfur hexafluoride (DB11104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dose of 4.8 mL administered intravenously one time
Trial: NCT04427293
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 12mg daily for 7 days prior to surgery
Trial: NCT04427293
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200 mg IV on day 1
Trial: NCT03551782
Drug: Cetrelimab 480 mg
RxNorm normalized name: Cetrelimab
DrugBank: Cetrelimab (DB15421)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetrelimab 480 mg will be administered intravenously (IV) on Cycle 1 Day 1, then every 4 weeks thereafter (Q4W).
Trial: NCT03551782
Drug: Apalutamide 240 mg
RxNorm normalized name: apalutamide 240 MG
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Apalutamide 240 mg (4\*60 mg) tablets per day will be administered orally.
Trial: NCT01082302
Drug: Polyphenon E (Veregen) 15% ointment
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times daily application on genital and perianal warts over 7 days
Trial: NCT00353002
Drug: Ametop (4% Amethocaine cream )
DrugBank: Sulfametopyrazine (DB00664)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00000276
Drug: Bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00029250
Drug: Garlic powder standardized to allicin
DrugBank: Garlic (DB10532)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00696878
Drug: Corifollitropin alfa
RxNorm normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
Trial: NCT00696878
Drug: Progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Progesterone administered vaginally at a dose of at least 600 mg/day.
Trial: NCT01912573
Drug: Intranasal (IN) naloxone
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01912573
Drug: Intravenous (IV) naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01912573
Drug: Intramuscular (IM) naloxone
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01912573
Drug: Intraosseus (IO) naloxone
RxNorm normalized name: Io-Shield
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02259114
Drug: Birabresib
RxNorm normalized name: Birabresib
DrugBank: Birabresib (DB15189)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birabresib 10, 20 and/or 40 mg oral capsules
Trial: NCT03937479
Drug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.375 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Trial: NCT03937479
Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 0.75 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Trial: NCT03937479
Drug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 1.5 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Trial: NCT03937479
Drug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● RPL554 3.0 mg twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Trial: NCT03937479
Drug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to receive one of the following treatment arms plus tiotropiuim:~● Placebo twice daily The approximate planned duration for each completed patient will be 14 days of run-in and 28 days of treatment with study medication.
Trial: NCT01120405
Drug: Xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01120405
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01459809
Drug: GLIMEPIRIDE
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: oral~Route of administration: oral
Trial: NCT01459809
Drug: METFORMIN
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: oral~Route of administration: oral
Trial: NCT02814058
Drug: zolpidem hemitartarate 1.75 mg - Sequency 1
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
Trial: NCT02814058
Drug: zolpidem hemitartarate 1.75 mg - Sequency 2
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
Trial: NCT02359903
Drug: Infliximab (BCD-055)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
Trial: NCT02359903
Drug: Infliximab (Remicade)
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02536664
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01555866
Drug: isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT00546481
Drug: methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
DrugBank: Methoxy polyethylene glycol-epoetin beta (DB09107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6 micrograms/kg every 2 weeks
Trial: NCT00546481
Drug: Epoetin
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed, iv, 3 times weekly
Trial: NCT01221506
Drug: Pazopanib
RxNorm normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 800 mg PO QD x 28 days
Trial: NCT03959293
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1500 mg by 1-hour IV infusion - Every 4 weeks
Trial: NCT03959293
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg by 1-hour IV infusion - Every 4 weeks
Trial: NCT00098995
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00098995
Drug: tirapazamine
RxNorm normalized name: Tirapazamine
DrugBank: Tirapazamine (DB04858)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04549480
Drug: Bosutinib capsule
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg dose of bosutinib pediatric capsule
Trial: NCT04549480
Drug: Bosutinib tablet
RxNorm normalized name: Bosutinib Tablets
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg dose of bosutinib tablet
Trial: NCT02347085
Drug: GFF MDI (PT003)
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01192880
Drug: Bitopertin
RxNorm normalized name: Bitopertin
DrugBank: Bitopertin (DB12426)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 10 mg or 20 mg of bitopertin.
Trial: NCT05812326
Drug: AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
Trial: NCT03942224
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT03942224
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT03942224
Drug: Ixazomib
RxNorm normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01465009
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
Trial: NCT02616731
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
Trial: NCT02616731
Drug: Diosmin
RxNorm normalized name: Diosmin
DrugBank: Diosmin (DB08995)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
Trial: NCT01485640
Drug: Lurasidone
RxNorm normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
Trial: NCT02944019
Drug: Edoxaban
RxNorm normalized name: Edoxaban
DrugBank: Edoxaban (DB09075)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Prescribed according to approved label
Trial: NCT01110252
Drug: Stem cells stimulation
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
Trial: NCT02066649
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administering carvedilol to patients diagnosed with large varices on endoscopy
Trial: NCT01585402
Drug: Etidronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.
Trial: NCT00120133
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00079313
Drug: Imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02761642
Drug: Epoetin Beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: All participants will receive epoetin beta at a dose of 30000 International Units (IU) as SC injection once every week for a total of 12 weeks. Adjustments in the dose will be implemented based on the participant's blood hemoglobin levels.
Trial: NCT00950651
Drug: Tramadol HCl Contramid® Once A Day
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
Trial: NCT00950651
Drug: Tramadol HCl Twice a day
RxNorm normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
Trial: NCT03768427
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin administered orally QD, either as two 10 mg tablets or as two 20 mg tablets
Trial: NCT03768427
Drug: Placebo for atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two placebo tablets matching atorvastatin administered orally QD for 84 days
Trial: NCT00467376
Drug: Insulin Glulisine
RxNorm normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 3 times a day before each meal
Trial: NCT01416363
Drug: Firategrast immediate release tablet
RxNorm normalized name: Firategrast
DrugBank: Firategrast (DB12732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
Trial: NCT00467376
Drug: Lispro
RxNorm normalized name: Lispro PRC
DrugBank: Insulin lispro (DB00046)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 times a day before each meal
Trial: NCT00467376
Drug: Insulin Glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: once daily
Trial: NCT01440361
Drug: Belimumab
RxNorm normalized name: Belimumab
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
Trial: NCT01440361
Drug: Normal saline placebo
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
Trial: NCT00499668
Drug: aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 125 mg orally for 7 days
Trial: NCT00499668
Drug: ondansetron hydrochloride
RxNorm normalized name: Ondansetron Hydrochloride
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 mg orally for 7 days
Trial: NCT01416363
Drug: Firategrast modified release tablet
DrugBank: Firategrast (DB12732)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.